Ketamine Tablets vs Troches

Tablets and troches are the two most commonly prescribed oral ketamine formulations. Despite both being taken by mouth, they work differently and produce meaningfully different pharmacokinetic profiles. Understanding these differences helps patients and prescribers select the formulation best suited to individual needs.

What Is the Actual Difference?

Ketamine tablets are solid dosage forms designed to be swallowed whole. The tablet passes through the stomach and small intestine, where ketamine is absorbed into the portal circulation and travels through the liver before reaching the systemic bloodstream. This first-pass hepatic metabolism converts 75-90% of the ketamine to norketamine and other metabolites.

Ketamine troches (also called lozenges or buccal tablets) are designed to dissolve slowly in the mouth over 15-30 minutes. Ketamine is absorbed through the buccal mucosa — the lining of the cheeks and under the tongue — partially bypassing the liver. Some of the dissolved troche is inevitably swallowed, so troches produce a combination of buccal and gastrointestinal absorption. See how to take ketamine tablets for practical administration guidance on both forms.

Head-to-Head Comparison

Bioavailability

The higher bioavailability of troches means that a lower milligram dose can achieve comparable plasma levels. A patient taking 200 mg via troche may achieve similar ketamine blood levels to a patient taking 300-400 mg via swallowed tablet.

Onset and Duration

Tablets: Onset in 30-60 minutes. Peak plasma levels at 1-2 hours. Effects lasting 3-5 hours total.

Troches: Onset in 15-30 minutes (buccal absorption begins while the troche is still dissolving). Peak plasma levels at 30-90 minutes. Effects lasting 3-4 hours total.

Troches generally produce a faster onset because buccal absorption delivers ketamine to the bloodstream without waiting for gastrointestinal transit and hepatic processing.

Administration

Tablets: Simple — swallow with water. No special technique required. Takes seconds.

Troches: Must be held in the mouth and allowed to dissolve over 15-30 minutes. Patients are often instructed to move the troche around the mouth to maximize mucosal contact. Some protocols advise holding saliva in the mouth rather than swallowing to maximize buccal absorption. The process requires patience and compliance.

Taste

This is a significant practical differentiator. Ketamine has a distinctly bitter, chemical taste that many patients find unpleasant.

Tablets: Minimal taste — the tablet is swallowed quickly and the taste exposure is brief.

Troches: Extended taste exposure for 15-30 minutes as the troche dissolves. Compounding pharmacies add flavoring (mint, citrus, berry), but the bitter ketamine taste is difficult to fully mask. Some patients find the taste intolerable and cannot comply with the full dissolution time.

Dosing Accuracy

Tablets: Highly consistent — each tablet contains a precise amount of drug. Dosing variability between tablets is minimal.

Troches: More variable in practice because absorption depends on how long the troche is held in the mouth, how much saliva is swallowed vs. retained, and the condition of the buccal mucosa. Two patients taking identical troches may absorb meaningfully different amounts.

Nausea

Tablets: Nausea is common (20-40%) because the full dose passes through the GI tract.

Troches: Potentially less nausea because buccal absorption reduces the amount of ketamine reaching the stomach. However, patients who swallow a significant portion of the dissolved troche may still experience nausea.

When Tablets Are the Better Choice

• Patients who cannot tolerate the taste of troches
• Patients who want the simplest possible administration
• Patients who need the most consistent, predictable dosing
• Patients who are uncomfortable holding medication in their mouth for extended periods
• Situations where dose titration requires precise milligram accuracy

When Troches Are the Better Choice

• Patients who need higher bioavailability without increasing the milligram dose
• Patients who experience significant nausea with swallowed tablets
• Patients who want faster onset of effects
• Patients comfortable with the dissolution technique and tolerant of the taste
• Clinicians targeting a more IV-like pharmacokinetic profile (faster onset, higher peak)

Switching Between Formulations

Patients and prescribers sometimes switch formulations during treatment:

Tablet to troche: Reduce the milligram dose by approximately 30-40% to account for the higher bioavailability. Monitor response and adjust.

Troche to tablet: Increase the milligram dose by approximately 30-50%. Monitor for reduced efficacy or increased GI side effects.

These are approximate guidelines — individual variation means that dose adjustments when switching should be guided by clinical response rather than strict conversion ratios.

The Bottom Line

Neither formulation is objectively superior. Tablets are simpler and more consistent; troches offer better bioavailability and faster onset. Many clinicians start with tablets for their ease of use and switch to troches if bioavailability or nausea is a concern. The best formulation is the one the patient will use consistently and tolerate well.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies